Industry advances are driving greater efficiency in biologics and viral vector manufacturing. Sanofi demonstrates intensified fed-batch processing with high-density seeding and simplified feeding protocols, boosting titers over twofold and lowering costs while reducing operational complexity. Similarly, Thermo Fisher scales viral vector downstream development to over 100 purifications per week using high-throughput chromatography and robotics, dramatically reducing feed volumes and development timelines. Fujifilm Biosciences introduced BalanCD HEK293 Perfusion A medium, optimized for suspension culturing and large-scale gene therapy viral vector production, enhancing GMP-compliant processes essential for commercialization.